Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Morphine Sulfate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ethypharm Gains EU Approval for Morphine Immediate Release Tablets
Details : Company received marketing authorisations (MA) for the 1st Immediate-Release orodispersible tablets of morphine, an opioid receptor agonist for the management of severe pain.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 12, 2021
Lead Product(s) : Morphine Sulfate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Medexus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Triamcinolone Hexacetonide is a longest-acting corticosteroid for intra articular injection. The companies have agreed to a small upfront fee along with milestone payments at the time of FDA approval, at commercial product launch, and upon certain sales ...
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Undisclosed
December 18, 2020
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Medexus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
KEY SERVICES
Reset All
Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.
